+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "T Cell Therapies"

Cell Separation Technologies - Global Strategic Business Report - Product Thumbnail Image

Cell Separation Technologies - Global Strategic Business Report

  • Report
  • November 2025
  • 193 Pages
  • Global
From
Viral Vector Manufacturing - Global Strategic Business Report - Product Thumbnail Image

Viral Vector Manufacturing - Global Strategic Business Report

  • Report
  • November 2025
  • 402 Pages
  • Global
From
Cell Dissociation - Global Strategic Business Report - Product Thumbnail Image

Cell Dissociation - Global Strategic Business Report

  • Report
  • November 2025
  • 193 Pages
  • Global
From
From
Synthetic Genes - Global Strategic Business Report - Product Thumbnail Image

Synthetic Genes - Global Strategic Business Report

  • Report
  • November 2025
  • 181 Pages
  • Global
From
Cell Analysis - Global Strategic Business Report - Product Thumbnail Image

Cell Analysis - Global Strategic Business Report

  • Report
  • November 2025
  • 273 Pages
  • Global
From
From
TCR Therapy- Pipeline Insight, 2025 - Product Thumbnail Image

TCR Therapy- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 280 Pages
  • Global
From
CAR-T - Pipeline Insight, 2025 - Product Thumbnail Image

CAR-T - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 450 Pages
  • Global
From
Advanced Hepatocellular Carcinoma- Pipeline Insight, 2025 - Product Thumbnail Image

Advanced Hepatocellular Carcinoma- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 200 Pages
  • Global
From
T-cell Surface Glycoprotein CD4 - Pipeline Insight, 2025 - Product Thumbnail Image

T-cell Surface Glycoprotein CD4 - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 90 Pages
  • Global
From
Anti-CD30 Therapies - Pipeline Insight, 2025 - Product Thumbnail Image

Anti-CD30 Therapies - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Anti-CD22 Therapies - Pipeline Insight, 2025 - Product Thumbnail Image

Anti-CD22 Therapies - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
CAR T-Cell Therapy For Non-Hodgkin's Lymphoma- - Pipeline Insight, 2025 - Product Thumbnail Image

CAR T-Cell Therapy For Non-Hodgkin's Lymphoma- - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
From
Anti-CD20 Antibody - Pipeline Insight, 2025 - Product Thumbnail Image

Anti-CD20 Antibody - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Head And Neck Cancer - Pipeline Insight, 2025 - Product Thumbnail Image

Head And Neck Cancer - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 240 Pages
  • Global
From
Advanced Urothelial Carcinoma - Pipeline Insight, 2025 - Product Thumbnail Image

Advanced Urothelial Carcinoma - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Anti-CD38 antibody - Pipeline Insight, 2025 - Product Thumbnail Image

Anti-CD38 antibody - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
TIM-3 Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

TIM-3 Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Loading Indicator

T Cell Therapies are a type of biotechnology that involves the use of a patient's own T cells to treat diseases. T cells are a type of white blood cell that play a key role in the body's immune system. T Cell Therapies involve the extraction of T cells from a patient, engineering them to recognize and attack specific targets, and then reintroducing them into the patient's body. This type of therapy has been used to treat a variety of cancers, including leukemia, lymphoma, and multiple myeloma. It has also been used to treat autoimmune diseases, such as rheumatoid arthritis and Crohn's disease. T Cell Therapies are a rapidly growing field of biotechnology, with many companies investing in research and development. Companies such as Kite Pharma, Juno Therapeutics, and Novartis are leading the way in developing and commercializing T Cell Therapies. Other companies, such as Gilead Sciences, Celgene, and Regeneron, are also investing in the field. Show Less Read more